COMMUNIQUÉS West-GlobeNewswire

Medline Inc. announces pricing of secondary offering of class A common stock
05/03/2026
NORTHFIELD, Ill., March 04, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today the pricing of a previously announced secondary offering of 75,000,000 shares of Medline Inc.’s Class A common [...]
Purisaki Berberine Patches Claims Evaluated: 2026 Consumer Report on Transdermal Berberine Delivery, Patch Absorption Science, and What Buyers Should Verify
05/03/2026
An informational 2026 consumer report examining Purisaki Berberine Patches' transdermal delivery claims, ingredient research context, pricing structure, and what to confirm before purchasing Wayne, NJ, March 04, 2026 ( [...]
SugarHarmony Consumer Concerns Under Investigation: Critiquing The Sugar Harmony Claims
05/03/2026
An informational 2026 consumer evaluation examining common SugarHarmony search queries, ingredient transparency concerns, marketing claim context, refund and fulfillment policy requirements, and what verification steps [...]
Monthly information on share capital and company voting rights
04/03/2026
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, March 04, 2026 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 Date Total number of shares in the [...]
HealthRecon Connect Achieves HITRUST r2 Certification Demonstrating the Highest Level of Information Protection Assurance
04/03/2026
HITRUST r2 Certification validates HealthRecon Connect’s commitment to strong cybersecurity and protecting sensitive healthcare data SOUTHLAKE, Texas, March 04, 2026 (GLOBE NEWSWIRE) -- HealthRecon Connect, a leading [...]
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
04/03/2026
–Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with this rare, devastating genetic neurodevelopmental disease– –Data support ongoing global Phase 3 [...]
AURORA SPINE CORPORATION ANNOUNCES AMENDMENT TO LOAN FROM INSIDER
04/03/2026
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Carlsbad, California, March 04, 2026 (GLOBE NEWSWIRE) -- Aurora Spine Corporation ("Aurora Spine" or the "Company") (TSXV [...]
Actuate Therapeutics to Present at The Citizens Life Sciences Conference
04/03/2026
CHICAGO and FORT WORTH, Texas, March 04, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for [...]
Sotera Health Announces Secondary Offering of Common Stock
04/03/2026
CLEVELAND, March 04, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) (the “Company”) today announced the launch of a secondary offering (the “Offering”) of 25 million shares of its common stock, par value $ [...]
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
04/03/2026
(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS, 04 mars 2026 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 Date Nombre total d’actions composant le [...]
Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma’s i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB
04/03/2026
FRIENDSWOOD, Texas, March 04, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data evaluating [...]
DBV Technologies to Participate in Upcoming March Investor Conferences
04/03/2026
Châtillon, France, March 4, 2026 DBV Technologies to Participate in Upcoming March Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical [...]
DBV Technologies annonce sa participation à plusieurs conférences investisseurs en mars
04/03/2026
Châtillon, France, le 4 mars (22 :30 CET) 2026 DBV Technologies annonce sa participation à plusieurs conférences investisseurs en mars DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Stock Market : DBVT [...]
SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update
04/03/2026
SCYNEXIS received a one-time non-refundable payment in Q4 2025 totalling $24.8 million from GSK SCYNEXIS announced dosing of the first patient using the intravenous (IV) formulation of SCY-247 in a Phase 1 study and [...]
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
04/03/2026
ZUG, Switzerland, March 04, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company. Attachment Notification of managers' [...]
Teladoc Health Announces Employee Inducement Award under NYSE Rule 303A.08
04/03/2026
NEW YORK, March 04, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in virtual care, today announced that it issued an inducement award to a new employee. Effective March 1, 2026, in [...]
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
04/03/2026
SAN DIEGO, March 04, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)- [...]
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
04/03/2026
LEXINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel [...]
Aquestive Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
04/03/2026
Reaffirms guidance to resubmit Anaphylm™ (dibutepinephrine) sublingual film NDA in Q3 2026; Type A meeting with FDA expected to occur within 30 days On track to submit regulatory applications for Anaphylm in Canada and [...]

Pages